Victory Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Victory Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5	Closed	-$8K	–	2706
2022 Q2	$8K	Hold	5	–	–	﹤0.01%	2664
2022 Q1	$6K	Sell	5 -1	-17%	-$2.51K	﹤0.01%	2696
2021 Q4	$27K	Buy	6 +1	+20%	+$6K	﹤0.01%	2674
2021 Q3	$34K	Hold	5	–	–	﹤0.01%	2708
2021 Q2	$48K	Hold	5	–	–	﹤0.01%	2665
2021 Q1	$42K	Buy	5 +1	+25%	+$9.45K	﹤0.01%	2678
2020 Q4	$32K	Hold	4	–	–	﹤0.01%	2482
2020 Q3	$26K	Hold	4	–	–	﹤0.01%	2419
2020 Q2	$31K	Sell	4 -3	-43%	-$21.8K	﹤0.01%	2422
2020 Q1	$46K	Buy	+7	New	+$74K	﹤0.01%	2798
2019 Q4	–	Sell	-2	Closed	-$21K	–	2689
2019 Q3	$21K	Buy	+2	New	+$22.3K	﹤0.01%	3022

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Victory Capital Management's AVTX Position: Q3 2022 in Review

Victory Capital Management sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 5 shares — an estimated $8K sold.

Victory Capital Management first reported a position in AVTX in Q3 2019 and held it in 11 quarters. The position peaked at $48K in Q2 2021. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

Victory Capital Management reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
Victory Capital Management sold 5 Avalo Therapeutics shares in Q3 2022, an estimated $8K.
Victory Capital Management first reported a position in Avalo Therapeutics in Q3 2019 and held it in 11 quarters.
Victory Capital Management's Avalo Therapeutics position peaked at $48K in Q2 2021.
18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.